Matt D Wasserman
Overview
Explore the profile of Matt D Wasserman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
48
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rozenbaum M, Perdrizet J, Li X, Wasserman M, Grant L, Hayford K, et al.
Infect Dis Ther
. 2022 Nov;
12(1):295-298.
PMID: 36376731
No abstract available.
2.
Perdrizet J, Farkouh R, Horn E, Hayford K, Sings H, Wasserman M
Expert Rev Vaccines
. 2022 Feb;
21(4):499-511.
PMID: 35191368
Introduction: Otitis media (OM) is a common childhood infection. Pneumococcal conjugate vaccines (PCVs) prevent OM episodes, thereby reducing short- and long-term clinical, economic, humanistic, and societal consequences. Most economic evaluations...
3.
Wasserman M, Perdrizet J, Grant L, Hayford K, Singh S, Saharia P, et al.
Infect Dis Ther
. 2021 Oct;
10(4):2701-2720.
PMID: 34633639
Introduction: The widespread implementation of pneumococcal conjugate vaccines (PCVs) has significantly reduced the burden of pneumococcal disease around the world. Although licensed 10-valent (PCV10) and 13-valent (PCV13) vaccines have considerably...
4.
Ghia C, Horn E, Rambhad G, Perdrizet J, Chitale R, Wasserman M
Infect Dis Ther
. 2021 Sep;
10(4):2289.
PMID: 34495488
No abstract available.
5.
Horn E, Wasserman M, Hall-Murray C, Sings H, Chapman R, Farkouh R
Expert Rev Vaccines
. 2021 Aug;
20(10):1291-1309.
PMID: 34424123
Introduction: Modeling analyses have attempted to quantify the global impact of pneumococcal conjugate vaccines (PCVs) on pneumococcal disease (PD), however these pediatric models face several challenges in obtaining comprehensive impact...
6.
Ghia C, Horn E, Rambhad G, Perdrizet J, Chitale R, Wasserman M
Infect Dis Ther
. 2021 Jul;
10(4):2271-2288.
PMID: 34313958
Introduction: Although the pneumococcal conjugate vaccine (PCV) has been introduced into select state immunization programs (SIPs) in India, many children remain unvaccinated. Recently, India's Advisory Committee on Vaccines & Immunization...
7.
Wilson M, McDade C, Perdrizet J, Mignon A, Farkouh R, Wasserman M
Infect Dis Ther
. 2021 Jul;
10(3):1765-1778.
PMID: 34250576
Introduction: Since 2010, 10-valent (PCV10) and 13-valent pneumococcal conjugate vaccines (PCV13) have been available as part of infant national immunization programs. Belgium is as one of the few countries that...
8.
Sings H, Gessner B, Wasserman M, Jodar L
Infect Dis Ther
. 2021 Feb;
10(1):521-539.
PMID: 33587245
Introduction: Limited changes in serotype 3 invasive pneumococcal disease (IPD) incidence rates after a decade of 13-valent pneumococcal conjugate vaccine (PCV13) introduction into several national immunization programs (NIP) have raised...
9.
Wasserman M, Sings H, Wilson M, Postma M, Breton M, McDade C, et al.
Infect Dis Ther
. 2018 Nov;
8(1):1-3.
PMID: 30460606
No abstract available.